×
About 35,308 results

ALLMedicine™ Pancreatic Cancer Center

Research & Reviews  12,151 results

NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance b...
https://doi.org/10.1002/1878-0261.13230
Molecular Oncology; Chen X, Zhang W et. al.

May 21st, 2022 - Low responsiveness to chemotherapy is an important cause of poor prognosis in pancreatic cancer. Smoking is a high-risk factor for pancreatic cancer and cancer resistance to gemcitabine; however, the underlying mechanisms remain unclear. 4-(methyl...

Outcomes of pancreatic cancer with liver oligometastasis.
https://doi.org/10.1002/jhbp.1184
Journal of Hepato-biliary-pancreatic Sciences; Takeda T, Sasaki T et. al.

May 21st, 2022 - Liver oligometastatic pancreatic cancer (PC) may have favorable outcomes. This study aims to evaluate outcomes and factors associated with overall survival (OS) of these patients. We retrospectively investigated consecutive PC patients with liver ...

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04840615

May 20th, 2022 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
https://clinicaltrials.gov/ct2/show/NCT03190941

May 20th, 2022 - Background: We generated an HLA-A*11:01-restricted murine T-cell receptor (mTCR) that specifically recognizes the G12V-mutated variant of KRAS (and other RAS family genes), expressed by many human cancers and constructed a single retroviral vector...

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
https://clinicaltrials.gov/ct2/show/NCT04896073

May 20th, 2022 - Background: Adenosquamous carcinoma of the pancreas (ASCP) is a highly aggressive variant of pancreatic ductal adenocarcinoma (PDA), the most common type of pancreas cancer. ASCP is estimated to account for 0.5-4% of the 55,000 people who are diag...

see more →

Guidelines  27 results

ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptib...
https://doi.org/10.1016/j.gie.2021.12.001
Gastrointestinal Endoscopy; Sawhney MS, Calderwood AH et. al.

Feb 21st, 2022 - ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations.|2022|Sawhney MS,Calderwood AH,Thosani NC,Rebbeck TR,Wani S,|diagnosis,genetics,

American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic c...
https://doi.org/10.1016/j.gie.2021.12.002
Gastrointestinal Endoscopy; Calderwood AH, Sawhney MS et. al.

Feb 21st, 2022 - American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence.|2022|Calderwood AH,Sawhney MS,Thosani NC,Rebbeck TR,Wani S,|diagnosis,gene...

Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-ba...
https://doi.org/10.1016/j.pan.2021.05.004
Pancreatology : Official Journal of the International Ass...

Jun 22nd, 2021 - Pancreatic cancer is the eighth most common cancer and the fifth most common cause of cancer-related death in Korea. To enable standardization of management and facilitate improvements in outcome, a total of 53 multi-disciplinary experts in gastro...

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2021.0017
Journal of the National Comprehensive Cancer Network : JN... Tempero MA, Malafa MP et. al.

Apr 13th, 2021 - Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provi...

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058005
Clinical & Translational Oncology : Official Publication ... Gómez-España MA, Montes AF et. al.

Mar 5th, 2021 - Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery i...

see more →

Drugs  54 results see all →

Clinicaltrials.gov  703 results

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
https://clinicaltrials.gov/ct2/show/NCT04840615

May 20th, 2022 - Background: LMB-100, and a closely related immunotoxin, SS1P, also targeting mesothelin, given intravenously, have been studied in Phase 1 clinical studies for mesothelioma and pancreatic cancer. LMB-100 given intravenously, results in systemic in...

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
https://clinicaltrials.gov/ct2/show/NCT03190941

May 20th, 2022 - Background: We generated an HLA-A*11:01-restricted murine T-cell receptor (mTCR) that specifically recognizes the G12V-mutated variant of KRAS (and other RAS family genes), expressed by many human cancers and constructed a single retroviral vector...

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
https://clinicaltrials.gov/ct2/show/NCT04896073

May 20th, 2022 - Background: Adenosquamous carcinoma of the pancreas (ASCP) is a highly aggressive variant of pancreatic ductal adenocarcinoma (PDA), the most common type of pancreas cancer. ASCP is estimated to account for 0.5-4% of the 55,000 people who are diag...

A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People With Advanced Pancreatic Cancer and BRCA Mutations
https://clinicaltrials.gov/ct2/show/NCT04150042

May 20th, 2022 - In the current clinical trial, participants with BRCA-related metastatic pancreatic cancer will receive a combination of melphalan, BCNU, low-dose ethanol, vitamin B12b, and vitamin C in conjunction with autologous stem cell infusion. The drug com...

Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy
https://clinicaltrials.gov/ct2/show/NCT04875325

May 18th, 2022 - Rationale: Radical resection combined with (neo)adjuvant chemotherapy offers the best chances for long-term survival for patients with resectable localized pancreatic ductal adenocarcinoma (PDAC). However, even after radical resection, almost all ...

see more →

News  1,144 results

Gallstone Disease May Be a Harbinger of Pancreatic Cancer
https://www.medscape.com/viewarticle/974050

May 16th, 2022 - The presence of gallstone disease may be a harbinger of pancreatic ductal adenocarcinoma (PDAC), researchers suggest after showing an association between the two in a SEER-Medicare database analysis. Patients with PDAC were six times more likely t...

Dodging Potholes From Cancer Care to Hospice Transitions
https://www.medscape.com/viewarticle/973719

May 10th, 2022 - I'm often in the position of caring for patients after they've stopped active cancer treatments, but before they've made the decision to enroll in hospice. They remain under my care until they feel emotionally ready, or until their care needs have...

Endoscopic ultrasound survives the sharks at AGA Tech Summit
https://www.mdedge.com/internalmedicine/article/254361/gastroenterology/endoscopic-ultrasound-survives-sharks-aga-tech
Jim Kling

May 5th, 2022 - After a 3-year, pandemic-induced hiatus, the American Gastroenterological Association’s Tech Summit returned to a “live” meeting in San Francisco. As usual, the highlight of the 2-day event, which is sponsored by the AGA Center for GI Innovation a.

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors
https://www.onclive.com/view/jdq443-demonstrates-early-efficacy-signals-in-kras-g12c-mutant-solid-tumors

May 2nd, 2022 - The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 (NCT04699188) trial presented at the 2022 AACR Annual Meeting....

Extra COVID Jab for Cancer Patients; VA to Cover More Cancers; Cancer's Origin Story
https://www.medpagetoday.com/hematologyoncology/othercancers/98467

Apr 29th, 2022 - The National Comprehensive Cancer Network endorsed a second COVID mRNA booster for immunocompromised individuals, bringing the total to five jabs, as three is considered standard for someone who is immunocompromised. In a first-quarter earnings st...

see more →

Patient Education  44 results see all →